SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending with intense debate following its earnings report and the recent policy proposal concerning Medicare Advantage rates for 2027. While some investors are calling it a "falling knife" and anticipate further declines due to perceived policy risks, others view it as a "great buying opportunity," arguing the market's reaction is an overcorrection for a fundamentally strong company. This ongoing discussion underscores broader uncertainty surrounding government influence on the managed care sector's future profitability.

Richtech Robotics, Inc. engages in the development of robotics and artificial intelligence. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is experiencing a surge in trading interest following its announced collaboration with Microsoft to integrate advanced agentic AI capabilities into its robotic systems. The community is actively discussing the potential for a short squeeze and significant upside, viewing the Microsoft partnership as a major catalyst. This development is positioning RR as a key player in the rapidly evolving AI and robotics sector, despite some ongoing debates about its immediate revenue impact and long-term valuation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending as investors eagerly anticipate significant hyper-scale data center contracts and strategic partnerships, building on its pivot into AI infrastructure and green energy. While many are bullish on its long-term growth potential and green energy focus, the community is actively discussing perceived stock manipulation and the need for new announcements from management to match the performance of its peers.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as investors assess its strategic role in the TikTok deal, which many bulls hail as a significant long-term boost for cloud revenue and AI infrastructure. This optimistic outlook is tempered by ongoing community discussion and analyst concerns regarding the company's substantial capital expenditures and increasing debt for AI buildout, leading to sharp divergence in investor sentiment.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is experiencing strong community discussion and upward price action driven by high anticipation for a significant buyout or partnership surrounding its "best in class" MASH drug, Pemvidutide, which holds Breakthrough Therapy Designation. Investors are emphasizing its differentiated safety profile and efficacy as key attractions for major pharmaceutical players, leading to widespread belief that the stock is currently undervalued. The sustained momentum and notable short interest are also fueling speculation of a potential short squeeze within the biotech sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors eagerly await its Q4 earnings, hoping for strong results driven by rapid store expansion and improving margins from moderating delivery price wars. Community conversation is heavily focused on persistent hopes for an uplisting from OTC, alongside excitement over the company's aggressive expansion into major markets like New York, directly challenging competitors. This narrative of robust growth and perceived undervaluation, supported by favorable analyst targets, continues to drive intense discussion.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending after securing significant federal financing and an equity stake from the U.S. government, alongside a substantial private placement, to advance its domestic rare-earth supply chain. This strategic backing, crucial for reducing reliance on foreign sources for critical minerals, has sparked intense investor interest, though community discussions reflect both strong bullish sentiment and frustration over market volatility.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is drawing significant attention following multiple announcements, including new enterprise and university quantum computer sales, a collaboration for U.S. air and missile defense, and advancements in its dual-platform annealing and gate-model technologies. The community is engaged in a lively debate, with proponents touting D-Wave's potential leadership in the evolving quantum sector, while others remain cautious regarding its high valuation against current revenue.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is currently trending as a highly volatile inverse natural gas ETF, with community discussion centered on its potential for a rebound following a significant natural gas price surge. Many investors are actively accumulating KOLD shares, anticipating that the recent spike in natural gas, driven by temporary extreme cold weather, is overextended and will soon reverse. The sentiment points to natural gas prices being 'over pumped' and likely to normalize as warmer forecasts emerge and supply concerns subside.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is generating significant buzz after its partner, Corvex, secured a long-term GPU leasing agreement involving NVIDIA H200 chips to scale AI infrastructure. The community is actively discussing the stock's exceptionally low float, driving expectations for a substantial short squeeze. Traders are comparing its potential to other recent low-float plays, fueled by this AI-related catalyst, despite some underlying concerns about future dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Florida Atlantic University commits $20 million to purchase and install a D-Wave Advantage2 annealing system.</li><li>D-Wave to establish its new corporate headquarters at the Boca Raton Innovation Center.</li><li>D-Wave is expected to showcase new hybrid solver capabilities using machine learning in quantum workflows at the Qubits 2026 conference later on Tuesday.</li></ul>Shares of D-Wave Quantum Inc. (QBTS) drew significant retail interest on Tuesday morning after rising over 5% in pre-market trading, fueled by fresh updates including a defense partnership and a deal with Florida Atlantic University.D-Wave Quantum announced that Florida Atlantic University (FAU) has committed $20 million to purchase and install a D-Wave Advantage2 annealing system at its Boca Raton campus, with deployment expected later in 2026.&nbsp;This system will serve as the foundation for a new collaboration between D-Wave and FAU, which could include a Quantum Applications Academy and support for research, training, and workforce development initiatives.&nbsp;D-Wave will also establish its new corporate headquarters at the Boca Raton Innovation Center.<h2 class="st-heading-2">More Collaborations</h2>In a separate announcement, D-Wave revealed a collaboration with Davidson Technologies and defense company Anduril Industries to develop quantum-classical hybrid applications for complex U.S. air and missile defense scenarios.Initial proof-of-concept tests using D-Wave’s Stride hybrid solver on the Advantage2 system demonstrated up to 10x faster solutions, a 9-12% improvement in threat mitigation, and the ability to intercept 45-60 additional missiles in a simulated 500-missile attack.The collaboration will expand to other defense challenges, including logistics, manufacturing, cyber defense, and course-of-action planning, the company added.At D-Wave’s Qubits 2026 conference later on Tuesday, the company is expected to showcase new hybrid solver capabilities using machine learning in quantum workflows, as well as progress on its technologies following the acquisition of Quantum Circuits earlier this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/QBTS">QBTS</a> was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/QBTS_jpg_8dd9a289c0.webp" alt="QBTS.jpg">One Stocktwits user sounded skeptical and highlighted the stock’s current valuation.<stembedurl>https://stocktwits.com/Shelby007/message/642988665</stembedurl>The stock has gained more than 300% over the past year, even as year-to-date declines stand at around 12%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ups-stock-rises-q4-beat-strong-2026-guidance/cmyavvvR4Le">UPS Stock Rises Pre-Market On Upbeat Guidance – CEO Calls 2026 As Inflection Year After Amazon Pullback</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, D-Wave Systems Inc. logo of a Canadian quantum computing company is seen on a smartphone screen.

What Triggered QBTS Stock’s Pre-Market Rally Today?

The company tied up with Davidson Technologies and defense company Anduril Industries to develop quantum-classical hybrid applications for U.S. air and missile defense scenarios.

Equity

<ul class="summary-bullets"><li>The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy.</li><li>The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial.</li><li>Previously, MannKind filed a supplemental FDA application to expand Afrezza’s use to patients aged four to 17, with a decision anticipated by May 29, 2026.</li></ul>Shares of MannKind Corp. (MNKD) gained more than 7% in pre-market trading on Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing information for Afrezza, its inhaled mealtime insulin used to improve glycemic control in adult patients with diabetes mellitus.The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy. The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial, which showed significantly improved post-meal glucose control after conversion to Afrezza, as recommended by the new dosing recommendations.“We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps. We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza’s established clinical profile,” said Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind Corporation.&nbsp;<h2 class="st-heading-2">Q3 Revenue Boosted By Afrezza Sales</h2>In November, the company posted a 17% increase in third-quarter (Q3) total revenue to $82.13 million, driven by strong growth in sales of its Afrezza inhaled insulin. Afrezza revenue climbed 23% to $18.5 million, supported by higher pricing and rising demand, while royalty income rose to $33.3 million.MannKind also submitted a supplemental application to the FDA seeking approval of Afrezza for patients aged four to 17. A regulatory decision is expected by May 29, 2026.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes. MNKD was among the top trending tickers at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MNKD_jpg_fd37ecdc2d.webp" alt="MNKD.jpg" width="930" height="85"><figcaption>MNKD's Sentiment Meter and Message Volumes at Premarket on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure>Meanwhile, one user didn’t see the FDA update as a major catalyst.<stembedurl>https://stocktwits.com/firefox2778/message/642859216</stembedurl>The stock has declined around 4.7% year-to-date and over 10.5% in the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ag-asml-hl-stocks-soar-silver-prices-record-high-110/cmy78kuR4WC">AG, ASM, HL Stocks Soar Pre-Market As Silver Blasts Past $110</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

Why Did MNKD Stock Jump Over 7% In Pre-Market Today?

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The offering includes 34.8 million shares at $5.75, the stock’s closing price on Tuesday.</li><li>Medtronic’s investment is expected to give it a post-offering ownership stake of between 16% and 19.99%.</li><li>Proceeds from the transactions will be used to support Anteris’ clinical strategy, including&nbsp; R&amp;D at v2vmedtech.</li></ul>Shares of Anteris Technologies Global Corp. (AVR) jumped sharply in pre-market trading on Wednesday after the structural heart specialist unveiled a $200 million equity raise alongside a sizable strategic investment from healthcare technology heavyweight Medtronic.<a href="https://stocktwits.com/symbol/AVR">AVR shares</a> were up around 17% at the time of writing and were on track to open at their highest levels since March 2025.Anteris announced a proposal to raise $200 million via a public offering of its common stock and grant underwriters a 30-day option to purchase up to an additional $30 million of shares at the public offering price.In a separate release, the company said the offer is to sell around 34.8 million shares at $5.75, the stock’s closing price on Tuesday.<h2 class="st-heading-2">Medtronic Investment</h2>Alongside the public offering, Anteris entered into a stock purchase agreement with Medtronic plc (MDT). Under the deal, Medtronic, through a wholly owned unit, will invest up to $90 million in Anteris common stock via a private placement priced in line with the public offering. The transaction is expected to give Medtronic a post-offering ownership stake of between 16% and 19.99% in Anteris.Proceeds from the transactions will be used to support Anteris’ clinical strategy, including continued patient recruitment and execution of the global PARADIGM pivotal trial for the DurAVR Transcatheter Heart Valve (THV) in severe aortic stenosis, expanding manufacturing capacity, and funding ongoing research and development (R&amp;D) at v2vmedtech, a privately owned medical technology company.The DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy aortic valve.&nbsp;<h2 class="st-heading-2">What Is Retail Saying?</h2>On Wednesday, retail sentiment for AVR flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes increased to ‘extremely high’ from ‘normal’ on Stocktwits. AVR was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/AVR_jpg_6c056947d5.webp" alt="AVR.jpg">One user expects the stock to hit $20 on the ‘bullish news’.<stembedurl>https://stocktwits.com/Redrooster79/message/642383722</stembedurl>However, another user was slightly skeptical about the dilution.<stembedurl>https://stocktwits.com/Rvazstocksfl/message/642363903</stembedurl>AVR stock has declined more than 4% over the past year but has gained around 12% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvidia-stock-rising-in-premarket-today/cmUDZxrR4Oz">Why Is Nvidia Stock Rising In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Why Did AVR Stock Surge Pre-Market Today? 

The company unveiled a $200 million dilution alongside a $90 million investment from healthcare technology heavyweight Medtronic.

AVR Stock Pops Pre-Market: Medtronic Backs $200M Capital Raise To Fund Key Trial

Relative Strength: Identifying Alpha in Market Weakness

The stocks that refuse to drop in a tough market are often the ones that will lead the next leg higher. By utilizing relative strength, investors can identify the best long opportunities. 

<ul class="summary-bullets"><li>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones.</li><li>Matrix-M adjuvant is a proprietary vaccine ingredient, used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets.</li><li>Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.</li></ul>Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market trading on Tuesday after the company signed a licensing agreement with Pfizer, granting the pharmaceutical giant non-exclusive rights to use Novavax’s Matrix-M adjuvant in up to two disease areas.Matrix-M adjuvant is a proprietary vaccine ingredient that improves the body’s immune response. It is made from naturally derived compounds and is used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets, according to Novavax.<h2 class="st-heading-2">What Is The Novovax-Pfizer Deal?</h2>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones. Novavax is also eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.Under the agreement, Pfizer will take full responsibility for the development and commercialization of its products, while Novavax will supply the Matrix-M adjuvant. The partnership strengthens Novavax’s long-term revenue potential.This comes after Novavax completed the transfer of U.S. and European marketing authorizations for its COVID-19 vaccine, Nuvaxovid, to Sanofi in November. The move resulted in a second $25 million milestone payment to Novavax, following the completion of the European Union marketing authorization transfer in October 2025.Novavax is expected to receive additional milestone payments and royalties tied to Nuvaxovid, Sanofi-developed combination products, and new vaccines that use Novavax’s Matrix-M adjuvant. Novavax also has long-standing partnerships with Japan’s Takeda and the Serum Institute of India.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> on Stocktwits remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes. NVAX was also among the top three trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/NVAX_jpg_1f4183eedd.webp" alt="NVAX.jpg">One bullish user said that the stock is undervalued.<stembedurl>https://stocktwits.com/ejaXstoXX/message/642272237</stembedurl>Another user was bullish about Matrix-M’s market potential.<stembedurl>https://stocktwits.com/P38FTD/message/642271830</stembedurl>The stock has declined around 6% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-ivf-stock-soaring-premarket/cmUum0oR4ap">INVO Fertility’s 350% Spike Puts Microcap IVF Stocks Back On Retail Radar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology

<ul class="summary-bullets"><li>ANKTIVA is an Interleukin-15 (IL-15) receptor agonist that helps develop and activate key cells that work to destroy cancer cells.</li><li>The company presented an overview of the clinical status of its papillary disease program, including more than five years of follow-up data.</li><li>The data demonstrated strong bladder preservation outcomes.</li></ul>ImmunityBio (IBRX) shares rose 6% in pre-market trading on Tuesday after the United States Food and Drug Administration (FDA) outlined a pathway for resubmitting its supplemental biologics license application (sBLA) for ANKTIVA in Bacillus Calmette Guérin (BCG)-unresponsive papillary bladder cancer, without requesting new trials.&nbsp;The company said it recently met with the FDA for a Type B end-of-phase meeting to review data spanning over five years.<h2 class="st-heading-2">The FDA Meeting</h2>During the meeting, ImmunityBio presented more than five years of follow-up data supporting the papillary disease indication. Long-term results, published in The Journal of Urology, showed bladder cancer–specific survival of around 96% at three years, with median survival not yet reached.The data also demonstrated strong bladder preservation outcomes, with cystectomy avoidance rates of 92% at one year and 82% at three years, alongside a safety profile consistent with ANKTIVA’s currently approved use in carcinoma in situ (CIS).Based on these discussions, the FDA recommended that ImmunityBio submit additional information for further evaluation to potentially support a resubmission of the sBLA initially filed in 2025. The Agency did not request any new clinical trials.“We have completed the assembly and analysis of the requested additional information and will submit it within the next 30 days for the Agency’s review,” said Richard Adcock, President and CEO of ImmunityBio.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells. It is already commercially available in the U.S. for NMIBC CIS, with or without papillary tumors, and has received approvals in the U.K. and Saudi Arabia, as well as conditional approval in the European Union.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes. IBRX was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_704152379c.webp" alt="IBRX.jpg">One user laid out the potential triggers for the stock.<stembedurl>https://stocktwits.com/end2war/message/642249657</stembedurl>Over the past year, the stock has gained 85,% and year-to-date, it has added more than 173%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rapt-stock-surge-63-in-pre-market-today/cmUuK0vR4aO">Why Did RAPT Stock Surge 63% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing

The company said it recently held end-of-phase talks with the United States Food and Drug Administration on its ANKTIVA application for treatment-resistant papillary bladder cancer.

This FDA Signal Is Powering IBRX Stock's Pre-Market Jump

<ul class="summary-bullets"><li>Morgan Stanley said the trends that led the space technology sector to outperform in 2025 are likely to carry over into 2026.</li><li>The brokerage firm also introduced an “Attractive industry view” for space technology through 2026.</li><li>Rocket Labs closed out 2025 with 21 successful Electron rocket launches.</li></ul>Rocket Lab USA Inc. (RKLB) drew investor interest with its shares rising 2.8% in pre-market trading on Friday, following a Morgan Stanley upgrade and a price target boost, driven by expectations of strong industry tailwinds in 2026.Morgan Stanley upgraded Rocket Lab to ‘Overweight’ from ‘Equal Weight’ and raised its price target to $105 from $67, according to The Fly. This represents a near 13% upside to the current share price of $93.2.RKLB stock is on track to open at an all-time high and was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">What Did Morgan Stanley Say?</h2>The brokerage cast a bullish view on the space technology industry in 2026, adding that the trends that drove the sector's outperformance in 2025 are likely to carry over into 2026.Morgan Stanley also introduced an “Attractive industry view” for space technology through 2026, driven by higher launch cadences, new products, policy support, and market maturation. The firm cited improved risk/reward for the upgrades it made, including the Canada-based MDA Space.<h2 class="st-heading-2">Recent Developments</h2>Rocket Lab was among the top-performing satellite companies in 2025, with its stock more than tripling in value. It closed out the year with 21 successful Electron rocket launches and saw its revenue climb nearly 40% in the first three quarters. For the fourth quarter (Q4), the company expects revenue between $170 million and $180 million, representing 32% upside from the previous corresponding period, assuming the upper end of the range.However, the feather in its cap came in the form of a $816 million contract from the U.S. Space Development Agency last month. Rocket Labs will design and build 18 satellites for the Tracking Layer Tranche 3 program. It is the largest single contract in the company’s history.Rocket Lab’s first launch this year will take place from New Zealand on January 20.<h2 class="st-heading-2">Retail Reaction</h2>Some users were bullish, despite retail sentiment on Stocktwits remaining in ‘neutral’ territory over the past 24 hours.One saw a long-term play till 2030.<stembedurl>https://stocktwits.com/G_Unit2023/message/642018735</stembedurl>Another user simply said it would be a perfect weekend if the stock crossed $100.<stembedurl>https://stocktwits.com/Stockanizer/message/642017893</stembedurl>&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-atos-stock-jump-10-in-pre-market-today/cmUlYPeR4Bc">Why Did ATOS Stock Jump 10% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a person holds a smartphone displaying the logo of Rocket Lab USA Inc.

RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally 

Morgan Stanley upgraded Rocket Lab to ‘Overweight’ from ‘Equal Weight’ and raised its price target to $105 from $67, according to The Fly.

<ul class="summary-bullets"><li>The trial compares Bacillus Calmette-Guérin (BCG) therapy alone with BCG combined with ANKTIVA.</li><li>Preliminary analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve cancer patients.</li><li>ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.</li></ul>ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.&nbsp;Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.“We look forward to the final accrual of this important registrational randomized trial in patients with BCG-naïve non-muscle-invasive bladder cancer, which represents a substantial proportion of newly diagnosed bladder cancer cases. The interim analysis is encouraging and consistent with findings in the approved BCG-unresponsive setting, where the duration of complete response has exceeded 47 months,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.Based on current progress, ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.<h2 class="st-heading-2">What Is The Trial About?</h2>The QUILT-2.005 is a clinical trial for Bacillus Calmette-Guérin (BCG) naïve non-muscle-invasive bladder cancer (NMIBC) that compares standard BCG therapy alone versus BCG combined with ANKTIVA, an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.In 2023, the FDA requested an interim analysis of the randomized trial to evaluate the added benefit of ANKTIVA when combined with BCG, focusing on complete response rates and the durability of response versus BCG alone.The analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve NMIBC patients. At six months, 85% of patients receiving the combination maintained a complete response, compared with 57% in the BCG-only group. At nine months, response rates were 84% with combination therapy versus 52% with BCG alone.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_3d2f27a76b.webp" alt="IBRX.jpg">One user was bullish about the company’s potential.<stembedurl>https://stocktwits.com/Amit18/message/642024906</stembedurl>Another user saw the stock as a long-term runner.<stembedurl>https://stocktwits.com/LeftyT/message/642025351</stembedurl>Over the past year, the stock has gained more than 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-set-for-all-time-high-morgan-stanley-boost/cmUlAaBR4B7">RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today 

The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.

 IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment 

<ul class="summary-bullets"><li>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa.</li><li>The company will also partner with regional pharmaceutical firm BioPharma Cigalah.</li><li>Enrolment for the QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter.</li></ul>ImmunityBio, Inc. (IBRX) drew retail attention on Wednesday as the stock jumped 8% after the Saudi Food and Drug Authority approved ANKTIVA in combination with the BCG (Bacillus Calmette-Guérin) vaccine to treat adults with BCG-unresponsive non-muscle invasive bladder cancer.The approval marks a major regulatory milestone, adding to existing authorizations in the United States and the United Kingdom, as well as conditional approval in the European Union.“We are pleased to bring ANKTIVA to Saudi patients with NMIBC, who otherwise have no viable options but life-altering surgery,” said Rich Adcock, Chief Executive Officer, ImmunityBio.<h2 class="st-heading-2">ImmunityBio’s Expansion Plans</h2>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa. The company will also partner with regional pharmaceutical firm BioPharma Cigalah. Management cited the rising incidence of bladder and other cancers in the region as a key driver behind the strategy.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.<h2 class="st-heading-2">ANKTIVA Developments</h2>Beyond bladder cancer, ANKTIVA is also drawing attention for its broader oncology potential. <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-surge-today/cmUXXCjR4Ig">Recent clinical data</a> from the QUILT-2.023 and QUILT-3.055 trials in non-small cell lung cancer (NSCLC) showed improved immune recovery and extended survival when ANKTIVA was combined with checkpoint inhibitors.Responding patients achieved a median survival of up to 21.1 months, significantly outperforming traditional chemotherapy outcomes.Meanwhile, enrolment for the company’s QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter (Q2) of 2026 and a potential biologics license application (BLA) by the end of the year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around ImmunityBio remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_1a3db9b5f3.webp" alt="IBRX.jpg">One user speculated that the approval could double the product revenue for the company.<stembedurl>https://stocktwits.com/Bc3345/message/641787673</stembedurl>One user sees the stock climb to $5 in the short term and $15-25 in the medium term.<stembedurl>https://stocktwits.com/AshvsEvilDead/message/64178170</stembedurl><a href="https://stocktwits.com/AshvsEvilDead/message/641781706">6</a>Over the past year, <a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> have risen around 21%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-clsk-stock-rising-premarket-texas-data-centre-deal/cmULgA7R4e0">CLSK Stock Receives Premarket Boost On Texas Data Center Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval

The approval in Saudi Arabia follows authorizations in the U.S. and the U.K., as well as a conditional approval in the European Union.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF